Do all patients with cancer thrombosis have the same risk of bleeding and recurrence? Particularities of lung cancer

Click to increase image sizeClick to decrease image size

Declaration of interest

L Bertoletti reports personal fees and non-financial support from Viatris; grant, personal fees and non-financial support from Bayer; personal fees and non-financial support from BMS-Pfizer; personal fees and non-financial support from Léo-Pharma; grants, personal fees and non-financial support from MSD; non-financial support from Johnson and Johnson; outside the submitted work. S Accassat reports non-financial support from Léo-Pharma and BMS-Pfizer. P Corbaux reports non-financial support from Astra-Zeneca and Novartis; outside the submitted work. G Poenou reports personal fees and non-financial support from Viatris; personal fees and non-financial support from Bayer; personal fees and non-financial support from BMS-Pfizer; grant, personal fees and non-financial support from Léo-Pharma. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Reviewer disclosures

Peer reviewers on this manuscript have no relevant financial or other relationships to disclose.

Additional information

Funding

This paper was not funded.